The KLF3 Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited pool of NCI-H1975 human lung adenocarcinoma cells harboring targeted disruption of the KLF3 gene. This polyclonal knockout format yields a heterogeneous population of loss-of-function alleles, minimizing clonal artifacts and ensuring a representative knockout model for functional studies.
NCI-H1975 is an EGFR-mutant (L858R/T790M) lung adenocarcinoma epithelial cell line widely used as a model for non-small cell lung carcinoma. The activating EGFR mutations drive constitutive kinase signaling and confer sensitivity to EGFR tyrosine kinase inhibitors, making it an ideal background for investigating oncogene addiction, drug resistance, and tumor progression in lung cancer.
KLF3 is a Kr??ppel-like factor transcriptional repressor that operates through the KLF3/CtBP repressor complex, recruiting the co-repressors CtBP1/CtBP2 and the histone deacetylase HDAC1. This complex silences target genes including CDKN1A and MYB, thus regulating cell proliferation, differentiation, and hematopoietic lineage commitment. KLF3 is modulated by upstream factors BCL6 and TGF-?? signaling and participates in pathways governing cell cycle regulation and transcriptional repression.
In the EGFR-mutant NCI-H1975 background, KLF3 knockout enables precise dissection of transcriptional repressor functions in lung adenocarcinoma. While KLF3 has established roles in hematopoiesis and B-cell malignancies, its contribution to lung cancer biology remains poorly characterized; therefore, this model provides a valuable system to investigate how loss of KLF3 affects cell cycle arrest, apoptosis, migration, and drug sensitivity. The interplay between KLF3-mediated repression of CDKN1A and MYB and EGFR-driven signaling can be systematically studied, offering insights into potential synthetic lethal interactions or resistance mechanisms.
The knockout cells are applicable to a variety of functional genomics screens, tumor suppressor investigations, and drug resistance mechanism studies. Typical assays include Western blotting and RT-qPCR for protein and mRNA expression profiling, MTS-based proliferation and colony formation assays to assess growth, migration and apoptosis assays for phenotypic characterization, and drug sensitivity assays to evaluate responses to EGFR-targeted agents such as erlotinib or osimertinib. Additionally, ChIP-qPCR and RNA-seq can be employed to define KLF3 target-gene networks and transcriptomic alterations. For more information or to discuss custom applications, contact Ascent Research.
